Masato Yagita

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Hideaki Tsuji, Ran Nakashima, Yuji Hosono et al. · Arthritis & Rheumatology · 2019 · 361 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.

M Tsudo, C K Goldman, Kathleen F. Bongiovanni et al. · Proceedings of the National Academy of Sciences · 1987 · 222 citations · Full text

Life Sciences, Immunology, Pathology +13

A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation

Masato Yagita, CL Huang, Hisanori Umehara et al. · Leukemia · 2000 · 187 citations

Life Sciences, Molecular Genetics, Oncology +13

Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis

Masanori Matsumoto, Hiromichi Ishizashi, Seiji Kato et al. · Thrombosis and Haemostasis · 2008 · 160 citations

Medicine, Hematology, Pathology +16

Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype

Shigeo Horiike, S Misawa, Hiroto Kaneko et al. · Leukemia · 1999 · 72 citations

Life Sciences, Genetics, Molecular Genetics +15